Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
Christoph Waldeyer(Universität Hamburg), Stefan Blankenberg(Universität Hamburg), Simona Giampaoli, Barbara Thorand(Helmholtz Zentrum München), Simona Costanzo(Istituto Neurologico Mediterraneo), Wolfgang Köenig(German Centre for Cardiovascular Research), Licia Iacoviello(Istituto Neurologico Mediterraneo), Kari Kuulasmaa(Finnish Institute for Health and Welfare), Frank Kee(Queen's University Belfast), Tanja Zeller(Universität Hamburg), Nataliya Makarova(German Centre for Cardiovascular Research), Christa Meisinger(University of Augsburg), Allan Linneberg(Frederiksberg Hospital), Francisco Ojeda(Universidad Complutense de Madrid), Veikko Salomaa(Finnish Institute for Health and Welfare), Pekka Jousilahti(Finnish Institute for Health and Welfare), Ulf Landmesser(Deutsches Herzzentrum der Charité), Teemu Niiranen(Edinburgh Napier University), Maurizio Ferrario(University of Insubria), Luigi Palmieri(Istituto Superiore di Sanità), Renate B. Schnabel(Universität Hamburg), Giovanni Veronesi(University of Insubria), Fabian J. Brunner, Paolo Brambilla(Azienda Ospedaliera San Gerardo), Stefano Signorini(University of Milano-Bicocca), Torben Jørgensen(University of Copenhagen), John Yarnell(Queen's University Belfast), Jukka Kontto(Finnish Institute for Health and Welfare)
Cited by 268
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Richness of human gut microbiome correlates with metabolic markers
|Nature|2013|4.7k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k